Madison-based Children's Wisconsin and UW Health have entered into a joint venture that merges their congenital heart disease programs, according to a Dec. 12 report from the Milwaukee Journal ...
Mesoblast’s Revascor gets US FDA’s regenerative medicine advanced therapy designation in children with congenital heart disease: New York Friday, December 6, 2024, 18:00 Hrs [ ...
FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart disease. NEW YORK, Dec. 04, 2024 (GLOB ...